Pain Management and the Opioid Epidemic Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use (2017) / Chapter Skim
Currently Skimming:
Appendix A: Data Sources and Methods
Appendix A: Data Sources and Methods
Pages 425-434
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 425... ...
In addition, the Cochrane Database of Systematic Reviews was queried, as were relevant federal, state, and local agencies and organizations for guidelines or other grey literature. The LexisNexis database was also reviewed for relevant legal and policy literature.
|
From page 426... ...
, pain conditions (acute pain, analgesia, arthritis, back pain, burn pain, cancer, chronic pain, chronic diseases, end of life, fibromyalgia, hyperalgesia, joint pain, knee pain, mental health disorders, neck pain, neuropathic pain, osteoarthritis, palliative care, post-traumatic stress, shoulder pain) , age (young adult, adult, geriatric, nursing home residents, pregnant women, neonatal, neonatal abstinence syndrome, neonatal opioid withdrawal syndrome, nursing mothers)
|
From page 427... ...
Commissioner of Food and Drugs Doug Throckmorton, M.D., Deputy Center Director for Regulatory Programs Center for Drug Evaluation and Research, FDA M.D., Director, Division of Anesthesia, Analgesia, and Sharon Hertz, Addiction Products M.D., Clinical Team Leader, Division of Anesthesia, Joshua Lloyd, Analgesia, and Addiction Products 3:10 pm Closing Remarks Richard Bonnie, L.L.B., Committee Chair 3:15 pm Adjourn Open Session
|
From page 428... ...
The second workshop, scheduled for November 4, 2016, in Washington, DC, will focus on the fifth element of the committee's statement of task: actions that the FDA and others can take now to address the opioid epidemic, including the FDA actions to be taken as part of development, review, and approval of pain medicines. 8:30 am Welcome and Opening Remarks Richard Bonnie, L.L.B., Committee Chair 8:45 am Session 1 – Perspectives on Progress and Future Directions in Clinical Pain Management and Provider Education David Clark, M.D., Ph.D., Palo Alto Veterans Affairs Pain Moderator: Clinic and Stanford University (Committee Member)
|
From page 429... ...
Non-Pharmacological Pain Management David Shurtleff, Ph.D., National Center for Complementary and Integrative Health, National Institutes of Health (15 min) Pain Management and Education at the National Research on Institutes of Health: Response to the 2011 IOM Report Relieving Pain in America David A
|
From page 430... ...
Naloxone for Opioid Safety M.D., M.I.A., San Francisco Department of Public Phillip Coffin, Health (15 min)
|
From page 431... ...
DISCUSSION (20 min) 4:25 pm Closing Remarks Richard Bonnie, L.L.B., Committee Chair 4:30 pm Adjourn
|
From page 432... ...
and others can take to address the opioid epidemic while taking into account the needs of pain patients, including FDA actions to be taken as part of development, review, and approval of pain medicines. 8:15 am Welcome and Introductions Richard Bonnie, L.L.B., Committee Chair 8:25 am Directions for Future Research to Support Regulatory Decision Making Nora D
|
From page 433... ...
Provider Education and Opioid Risk Evaluation and Mitigation Strategies Daniel P Alford, M.D., M.P.H., Boston University (15 min)
|
From page 434... ...
DISCUSSION (10 min) 3:15 pm Public Comment/Continued Discussion of Day's Presentations Richard Bonnie, L.L.B., Committee Chair 3:55 pm Closing Remarks Richard Bonnie, L.L.B., Committee Chair 4:00 pm Adjourn
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.